Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: A randomised study

Gut

Volumn 38, Issue 5, 1996, Pages 770-774

  Elsayed, S S ^a   Shiha, G ^a   Hamid, M ^a   Farag, F M ^a   Azzam, F ^a   Awad, M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

propranolol; sclerotherapy; variceal rebleeding

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS STRICTURE; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERMETHOD COMPARISON; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 0029937411     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.5.770     Document Type: Article

References (35)

1. Graham DY, Smith JL. The course of patients after variceal haemorrhage. Gastroenterology 1981; 80: 800-9.
2. Cordeiro F. Variceal sclerosis in schistosomatic patients, a 5-years follow-up. Gastrointest Endosc 1990; 36: 475-8.
3. DeDombal FT, Clarke JR, Clamp SE, Malizia G, Kotwal MR, Morgan AG, et al. Prognostic factors in upper gastrointestinal bleeding. Endoscopy 1986; 18 (suppl 2): 6-10.
4. Hashizume M, Kitano S, Koyangi N, Tanoue K, Ohta M, Wad H, et al. Endoscopic injection sclerotherapy for 1000 patients with oesophageal varices. A nine-year prospective study. Hepatology 1992; 15: 69-75.
5. Terblanche J, Bornman PC, Kahn D, Jonker MA, Campbell JAH, Wright J, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A 5-years controlled trial. Lancet 1983; ii; 1328-32.
6. Yassin YM, Sherif SM. Randomized controlled trial of injection sclerotherapy for bleeding oesophageal varices. Br J Surg 1983; 70: 20-2.
7. Korula J, Balart LA, Radvan G, Zweiban BE, Larson AW, Kao HW, et al. A prospective randomized controlled trial of chronic oesophageal variceal sclerotherapy. Hepatology 1985; 5: 814-8.
8. Garrett KO, Reilly JJr, Schade RR, Van Thiel DH. Sclerotherapy of oesophageal varices, long-term results and determinants of survival. Surgery 1988; 104: 819-23.
9. Lebrec D, Corbic M, Nouel O, Benhamon JP. Propranolol a medical treatment for portal hypertension. Lancet 1980; ii: 180-2.
10. Lebrec D, Poynard T, Hillon P, Benhamon JP. Propranolol in gastrointestinal bleeding in cirrhosis. N Engl J Med 1982; 306: 1551.
11. Burroughs AK, Jenkins WJs, Sherlock S, Dunk A, Walt RP, Osuaporo T, et al. Controlled trials of propranolol for the prevention of recurrent variceal haemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539-42.
12. Villeneuve JP, Pomier G, Infante-Rivard C, Willems B, Huet PM, Marlean D, et al. Propranolol for the prevention of recurrent variceal bleeding. A controlled trial Hepatology 1986; 6: 1239-43.
13. Westaby D, Melia W, Hegarty J, Gimson AES, Stellon AJ, Williams R, et al. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology 1986; 6: 673-5.
14. Kanazawa H, Watari A, Matsusaka S, Tada N, Miyata K, Saitch H, et al. Prospective controlled study of elective sclerotherapy plus oral propranolol for prevention of recurrent bleeding in cirrhotics with recent variceal haemorrhage (English abstract). Nippon Shokakibyo Gakkai Zashi 1991; 88: 1341-8.
15. Vinel JP, Lamouliatte H, Cales P, Combis JM, Roux D, Desmorat H, et al. Propranolol reduces the rebleeding rate during endoscopie sclerotherapy. A randomized study. Gastroenterology 1990; 98 (A): 644.
16. Kaplan EL, Meier J. Journal of the American Statistical Association 1958; 53: 457-82.
17. Ramos OL, Saad F, Lesser WT. Portal haemodynamics and liver cell function in hepatic schistosomiasis. Gastroenterology 1964; 47: 241-7.
18. Abd El Raouf L. Pattern of some viral antibodies in transfused patients [thesis]. Mansoura Faculty of Medicine, Egypt, 1991.
19. Lyra LG, Reboucas G, Andrad ZA. Hepatitis B surface-antigen carrier state in hepatosplenic schistosomiasis. Gastroenterology 1976; 71: 641-5.
20. Lundell L, Leth R, Lind T, Lonroth H, Sjovall M, Olbe L. Evaluation of propranolol for prevention of recurrent bleeding from oesophageal varices between sclerotherapy sessions. Acta Chir Scand 1990; 156: 711-5.
21. Terblanche J. The surgeon role in management of portal hypertension. Ann Surg 1989; 209: 381-95.
22. Westaby D, William R. Follow-up study after sclerotherapy. Scand J Gastroenterol 1984; 19: 71-4.
23. Jensen LS, Krarup N. Propranolol may prevent recurrence of oesophageal varices after obliteration by endoscopic sclerotherapy. Scand J Gastroenterol 1990; 25: 352-6.
24. Binmoeller H, Grimm H, Soehendra N. Treatment of oesophageal varices. Endoscopy 1992; 24: 52-7.
25. Jensen LS, Krarup N. Propranolol in prevention of rebleeding from oesophageal varies during the course of endoscopie sclerotherapy. Scand J Gastroenterol 1989; 24: 339-45.
26. Vickers C, Rhodes J, Hillinbrand P, Bradby H, Hawker P, Dykes P, et al. Prospective controlled trial of propranolol and sclerotherapy for prevention of rebleeding from oesophageal varices. Gut 1987; 28: A1359.
27. Westaby D, Polson RJ, Gimson AE, Haves PC, Hayllar J, Williams R. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variccal bleeding. Hepatology 1990; 12: 353-9.
28. Balanzo J, Such J, Sainz S. Long-term survival and severe rebleeding after variceal sclerotherapy. Surg Gynecol Obstet 1990; 171: 489-92.
29. Rossi V, Cales P, Burtin P, Chameau J, Person B, Pujol P, Valentin S. Prevention of recurrent variceal bleeding in alcoholic-cirrhotic patients. Prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991; 12: 283-9.
30. O'Connor KW, Lehman G, Yune H, Brunelle R, Christiansen P, Hast J, et al. Comparison of three nonsurgical treatments for bleeding esophageal varices. Gastroenterology 1989; 96: 899-906.
31. Routledge PA, Shand DG. Clinical pharmacokinetic of propranolol. Clin Pharmacokinet 1979; 4: 73-90.
32. Wood AJ, Kornhauser DM, Wilkinson DG, Shand DG, Branch RA. The influence of cirrhosis on steady state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet 1978; 3: 478-87.
33. Tarver D, Walt PR, Dunk AA, Jenkins WJ, Sherlock S. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. BMJ 1983; 287: 585.
34. Haves PC, Crichton S, Shepherd AN, Bouchier IAD. Propranolol in chronic liver disease: a controlled trial of its effect and safety over twelve months. Q J Med 1987; 246: 823-34.
35. Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices. A multicenters randomized clinical trial. Hepatology 1989; 8: 1-5.